DVAX Dynavax Technologies Corporation

3.25
+0.08  (+3%)
Previous Close 3.17
Open 3.32
Price To Book 32.5
Market Cap 280,113,480
Shares 86,188,763
Volume 1,590,742
Short Ratio
Av. Daily Volume 1,557,683
Stock charts supplied by TradingView

NewsSee all news

  1. Dynavax Provides Business Update on COVID-19 Pandemic Impact

    EMERYVILLE, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today provided a business

  2. Dynavax and CEPI Announce Collaboration to Support Global Effort to Develop a Vaccine for Coronavirus (COVID-19)

    EMERYVILLE, Calif., March 26, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and the Coalition for

  3. Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant

    Dynavax is providing CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, to support the rapid development of Clover's COVID-19 vaccineClover advancing evaluation of its protein-based coronavirus

  4. Dynavax Announces Fourth Quarter and Full Year 2019 Financial Results

    Full year 2019 HEPLISAV-B® net product revenue of $34.6 million, in line with upwardly-revised guidanceAim to grow 2020 HEPLISAV-B® net product revenue by approximately 70 percent over 2019Advancing efforts to leverage

  5. Dynavax Announces Collaboration with the University of Queensland and the Coalition for Epidemic Preparedness (CEPI) Focused on the Development of a Coronavirus (COVID-19) Vaccine

    EMERYVILLE, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it is

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Announced May 23, 2019 that it will discontinue investment in this program.
SD-101 + Pembrolizumab
Melanoma and head and neck squamous cell carcinoma (HNSCC)
CRL February 25, 2013 and November 14, 2016. Advisory Committee Meeting July 28, 2017 voted 21 -1 in favor of recommending approval. Final approval announced November 9, 2017.
HEPLISAV-B
Hepatitis B
Phase 2a trial did not meet primary endpoint - November 29, 2018.
AZD1419
Asthma
Announced May 23, 2019 that it will discontinue investment in this program.
DV281
Non-small Cell Lung Cancer (NSCLC)
Phase 1 commencement of enrolment announced May 2, 2019.
HEPLISAV-B
End Stage Renal Disease on Dialysis

Latest News

  1. Dynavax Provides Business Update on COVID-19 Pandemic Impact

    EMERYVILLE, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today provided a business

  2. Dynavax and CEPI Announce Collaboration to Support Global Effort to Develop a Vaccine for Coronavirus (COVID-19)

    EMERYVILLE, Calif., March 26, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and the Coalition for

  3. Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant

    Dynavax is providing CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, to support the rapid development of Clover's COVID-19 vaccineClover advancing evaluation of its protein-based coronavirus

  4. Dynavax Announces Fourth Quarter and Full Year 2019 Financial Results

    Full year 2019 HEPLISAV-B® net product revenue of $34.6 million, in line with upwardly-revised guidanceAim to grow 2020 HEPLISAV-B® net product revenue by approximately 70 percent over 2019Advancing efforts to leverage

  5. Dynavax Announces Collaboration with the University of Queensland and the Coalition for Epidemic Preparedness (CEPI) Focused on the Development of a Coronavirus (COVID-19) Vaccine

    EMERYVILLE, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it is

  6. Dynavax to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 11

    EMERYVILLE, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report fourth quarter and

  7. Dynavax to Present at the Cowen 40th Annual Health Care Conference

    EMERYVILLE, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan

  8. Dynavax Appoints Ryan Spencer as Chief Executive Officer and to Board of Directors

    EMERYVILLE, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan

  9. Dynavax Announces Partnership with Albertsons Companies' Pharmacies to Offer HEPLISAV-B® Hepatitis B Vaccine to Patients Nationwide

    - Partnership at 1,700 pharmacies nationwide with special focus on people living with diabetes- People living with diabetes are two times more likely to become infected with hepatitis B virus and up to four times as

  10. Dynavax Announces HEPLISAV-B Post-Marketing Requirement Interim Report Completed

    EMERYVILLE, Calif. , Dec. 03, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it has

  11. Dynavax to Present at the Stifel 2019 Healthcare Conference

    EMERYVILLE, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan

  12. Dynavax Announces Third Quarter 2019 Financial Results

    Third quarter 2019 HEPLISAV-B® net product revenue of $10.2 millionRaising revenue expectation range to $34-$36 million for full year 2019Conference call to be held today at 4:30 p.m. ET/1:30 p.m. PT EMERYVILLE, Calif.,

  13. Dynavax to Present at the 2019 Cantor Global Healthcare Conference

    BERKELEY, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ:DVAX), today announced that Ryan Spencer, Senior Vice President, Commercial, and Interim Co-President, will present at the